Functional Mobility For A Patient With Myelodysplastic Syndrome, Chronic GVHD, And Corticosteroid Use: A Case Report by Deardorff, Alyssa
University of New England
DUNE: DigitalUNE
Case Report Papers Physical Therapy Student Papers
12-2018
Functional Mobility For A Patient With
Myelodysplastic Syndrome, Chronic GVHD, And
Corticosteroid Use: A Case Report
Alyssa Deardorff
University of New England
Follow this and additional works at: https://dune.une.edu/pt_studcrpaper
Part of the Physical Therapy Commons
© 2018 Alyssa Deardorff
This Course Paper is brought to you for free and open access by the Physical Therapy Student Papers at DUNE: DigitalUNE. It has been accepted for
inclusion in Case Report Papers by an authorized administrator of DUNE: DigitalUNE. For more information, please contact bkenyon@une.edu.
Recommended Citation
Deardorff, Alyssa, "Functional Mobility For A Patient With Myelodysplastic Syndrome, Chronic GVHD, And Corticosteroid Use: A
Case Report" (2018). Case Report Papers. 97.
https://dune.une.edu/pt_studcrpaper/97
Deardorff, Functional Mobility for a Cancer Survivor with Chronic GVHD and Corticosteroid Use 
 
1 
 
 1 
Functional Mobility for a Patient with Myelodysplastic Syndrome, Chronic GVHD, and 2 
Corticosteroid Use: A Case Report 3 
 4 
 5 
 6 
 7 
 8 
 9 
Alyssa Deardorff, BS, is a DPT student at University of New England 716 Stevens Ave. 10 
Portland, ME 04103 11 
Address all correspondence to: adeardorff@une.edu 12 
 13 
The author acknowledges Amy Litterini PT, DPT, for assistance and conceptualization of this 14 
case report, Melanie Migues PT, DPT, for supervision and oversight of patient care, and the 15 
patient for participating. 16 
 17 
The patient signed an informed consent form allowing the use of medical information for this 18 
case report. The patient was educated on the Health Insurance Portability and Accountability Act 19 
(HIPPA) and received formal paperwork outlining the definition of HIPPA and appropriate 20 
disclosure of personal health information. 21 
 22 
 23 
Key Words: Myelodysplastic Syndrome, GVHD, Physical Therapy, Corticosteroids 24 
Deardorff, Functional Mobility for a Cancer Survivor with Chronic GVHD and Corticosteroid Use 
 
2 
 
 25 
      26 
27 
Deardorff, Functional Mobility for a Cancer Survivor with Chronic GVHD and Corticosteroid Use 
 
3 
 
ABSTRACT           28 
Background: The use of corticosteroids to treat chronic graft-versus-host-disease (cGVHD) is 29 
common in oncological treatment. However, the long-term complications of cGVHD and 30 
prolonged use of corticosteroids have not been reported in terms of the benefits of physical 31 
therapy (PT) interventions.  The purpose of this case report was to report the impact of PT 32 
interventions for an individual with a cancer diagnosis having received an allogenic-stem cell 33 
transplant (allo-SCT) with the long-term complications associated with cGVHD, long-term 34 
corticosteroid use, and cancer survivorship. 35 
Case Description: The patient was a 73-year-old male diagnosed with Myelodysplastic 36 
Syndrome and received an allo-SCT two years prior to initial evaluation. After a multitude of 37 
tests, his primary diagnosis was paraplegia with unclear etiology. The patient had weakness in 38 
his bilateral lower extremity’s proximal musculature (right lower extremity greater impaired than 39 
left) and loss of bowel/bladder function. The proposed plan of care included therapeutic exercise, 40 
neuromuscular re-education, self-care/home management, and gait training. 41 
Outcomes: After receiving both corticosteroid and PT interventions, the patient increased 42 
strength and mobility as shown by his improvement with transfers (Functional Independence 43 
Measure score from 4 to 6), gait (distance from 2 feet to 850 feet), and ability to complete 44 
balance and strength exercises consecutively and independently. He was discharged with the 45 
ability to walk with an assistive device and navigate his home and community environments 46 
safely.  47 
Discussion: Despite the lack of evidence for therapeutic interventions in patients with chronic 48 
corticosteroid use, cGVHD, and allo-SCT patients, this specific example shows the progress and 49 
accomplishments one can make with PT to optimize functional independence. Future research 50 
requires a greater focus on long-term complications and management of allo-SCTs including 51 
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rehabilitation.  52 
INTRODUCTION/BACKGROUND and PURPOSE  53 
Myelodysplastic Syndromes (MDS) are a type of cancer in which blood-producing cells 54 
in the bone marrow function abnormally, causing normal blood cells to die earlier.1 The most 55 
prevalent type of MDS, MDS with multilineage dysplasia, causes two of the three blood cell 56 
types (white blood cells, red blood cells, or platelets) to be low; however, there are several types 57 
of MDS.1 Approximately one in three individuals with MDS will develop Acute Myeloid 58 
Leukemia (AML), which is why MDS is often called pre-leukemia.1 It  has been estimated that 59 
approximately 10,000 cases of MDS are diagnosed each year in the United States.2 The treatment 60 
for MDS can include chemotherapy, supportive therapy, a stem cell transplant (SCT), and/or 61 
clinical trials.3 62 
A SCT can serve as the only potential curative treatment for individuals with MDS.3 63 
Types of SCTs include allogenic and autologous. See Table 1 for SCT information. An allogenic 64 
stem cell transplant (allo-SCT) involves collecting a matched donor’s stem cells and introducing 65 
them to the patient to produce a graft-versus-tumor-effect, in which the donor’s immune system 66 
combats the patient’s cancer.4 However, patients receiving an allo-SCT are at risk for 67 
complications both during the acute stages, and long after, their SCT.5  68 
Long-term complications after an allo-SCT span all body systems and are commonly due 69 
to graft-versus-host-disease (GVHD).5 GVHD causes the donor’s cells to attack both the 70 
malignancy and the patient’s healthy cells.4 There is both acute and chronic GVHD.5,6 A 71 
systematic review found that chronic GVHD (cGVHD) developed in approximately 70% of 72 
patients following an allo-SCT.5 73 
Once acquired, the treatment for acute and chronic GVHD is often steroids such as 74 
glucocorticoids (GC), which can have a detrimental effect on muscle strength, immune function, 75 
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weight, and mood.5 Recent research indicates that greater than 90% of patients who underwent 76 
an allo-SCT have at least one chronic health impairment.5 Ultimately, due to the risk for 77 
musculoskeletal and neurological impairments from the SCT process, there is a necessity for 78 
skilled rehabilitation intervention.  79 
A retrospective study included patients receiving GC for GVHD and reported on their 80 
adherence to a rehabilitation program in a sub-acute rehabilitation setting.6 Of those who 81 
completed their full plan of care (POC) (56%), there were improvements in the functional 82 
measures; however, the improvements were not statistically significant and some even declined 83 
in function.6 Ultimately, the findings report SCT patients, especially those receiving GC 84 
treatment, are likely to participate in exercise interventions granted that their condition did not 85 
worsen.6 Overall, these programs are necessary for patients post allo-SCT also taking GC due to 86 
the potential negative side effects on muscle strength such as the patient described in this case 87 
report. However, current research revolves primarily around the acute and sub-acute stages of 88 
patients post allo-SCT and does not consider long-term treatment needs.  89 
Furthermore, Morishita et al7 conducted a study including patients post allo-SCT who 90 
were prescribed corticosteroids. Results indicated that increased corticosteroid dose was 91 
associated with decreased grip and knee extensor strength.7 This study also considered the 92 
impact of physical therapy (PT) frequency on the above measures. Low physical function was 93 
correlated to high corticosteroid dose, low frequency of PT, and increased fatigue.7 Current 94 
research has not considered the effect of increased frequency of PT in patients with chronic GC 95 
usage, cGVHD, and additional comorbidities associated with a cancer diagnosis such as low 96 
blood counts and fatigue.  97 
 This case report is necessary due to the lack of published literature regarding the PT 98 
management for individuals with cGVHD and the long-term effects of allo-SCTs. Specifically, 99 
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there is a lack of literature discussing how PT impacts patients with steroid myopathy caused by 100 
high dose steroid therapy for treatment of GVHD. Lee et al8 studied patients with MDS/AML 101 
who had an allo-SCT and were diagnosed with acute GVHD. Of 70 patients identified, 29 (41%) 102 
had steroid myopathy.8 However, no literature reported on the effects of PT intervention for 103 
patients with cGVHD who continue to take GC for maintenance. Additionally, no current 104 
literature has identified a successful therapeutic approach for the treatment of patients with 105 
functional and strength deficits due to allo-SCTs.  Therefore, the purpose of this case report is to 106 
describe PT interventions for an individual with a cancer diagnosis who received an allo-SCT 107 
and subsequently had long-term complications associated with cGVHD, long-term GC use, and 108 
cancer survivorship.       109 
 110 
Patient History and Systems Review      111 
The following patient consented to participate in this case study. A 73-year-old male was 112 
diagnosed with MDS six years before his IE. Prior to an allo-SCT, he had multiple rounds of 113 
Decitabine, a form of chemotherapy specific to treatment of MDS. He underwent an allo-SCT 114 
two years prior to IE and was diagnosed with GVHD of the skin shortly after. His skin GVHD 115 
responded well to steroids, specifically Prednisone; however, once he started tapering the 116 
steroids, the rash reoccurred. Therefore, he was on Prednisone for an extended period of time, 117 
ending one year prior to IE. After discontinuing Prednisone, he was readmitted to the hospital 118 
with Respiratory Syncytial Virus. He was tested for GVHD of the gastrointestinal tract and the 119 
results revealed grade 1 GVHD of the duodenum, antrum, and right and left colon. Therefore, he 120 
was given high dose steroids to alleviate his GVHD and Sirolimus as an immunosuppressant.  121 
His past medical history included: diverticulitis; subclinical hypothyroidism; anemia; 122 
immunodeficiency disorder; electrolyte and fluid disorders; drug/chemical induced diabetes 123 
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mellitus with hyperglycemia; deep vein thromboses; and long-term use of insulin and systemic 124 
steroids. His pertinent familial history included a brother with MDS and a sister with lung 125 
cancer. See Appendix 1 for his medication list.  126 
The patient was admitted to an acute care cancer center (ACCC) days before his IE with 127 
reported progressive weakness in his bilateral lower extremities (BLE) for the previous six 128 
weeks. He was on vacation when he first noticed his symptoms, and subsequently required a 129 
rolling walker (RW) for ambulation. At that point, he sought care and received steroid treatment 130 
which alleviated his symptoms allowing him to ambulate with a cane. After he returned from 131 
vacation, he continued to lose strength and sensation of his BLE causing him to resort back to 132 
using a RW for household ambulation. Ultimately, he went to the emergency center (EC) after 133 
losing function of his BLE and bladder/bowel control. His initial diagnosis was paraplegia with 134 
loss of bladder/bowel function and Brown Sequard Syndrome. However, after multiple tests, 135 
Brown Sequard Syndrome was ruled out as well as viral meningitis, influenza, E. coli, Listeria, 136 
Neisseria, Streptococcal pharyngitis, Cytomegalovirus, Epstein-Barr virus, and cryptococcal 137 
antigen. A magnetic resonance imaging (MRI) of the spine showed no cord compression 138 
however, it showed moderate to severe stenosis at the C5-6 level and mild degenerative joint 139 
disease. A computed tomography (CT) scan of the head was negative. The patient had multiple 140 
lumbar punctures, all of which were negative. An electromyography revealed moderate 141 
generalized axonal sensorimotor polyneuropathy with chronic changes and chronic myopathy. 142 
However, this was not the root cause of his progressive functional decline, and his primary 143 
diagnosis remained paraplegia with unclear etiology. The patient was frustrated with the 144 
uncertainty of the cause of his weakness; however, he maintained a positive attitude and was 145 
motivated to improve his strength and ambulation abilities in order to return to his prior level of 146 
function (PLOF). See Appendix 2 for systems review results.  147 
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Prior to his admission, he was a retired chemical engineer who enjoyed spending time 148 
with his family and tending to his yard. He had a strong support system including his wife and 149 
children which were positive factors in his recovery. He lived in a two-story home with his 150 
bedroom/bathroom on the main level and no stairs to enter. He had a walk-in-shower and shower 151 
chair. He also noted he owned a RW and cane.   152 
Examination – Tests and Measures        153 
Upon IE, the patient’s BLE strength was evaluated using manual muscle testing (MMT) 154 
in a seated position. See Table 2 for MMT scores. Light touch sensation was assessed and was 155 
within normal limits (WNL), however, the patient noted chemotherapy induced peripheral 156 
neuropathy (CIPN) in his bilateral feet. The patient reported painful paresthesias over his right 157 
rib cage and BLE induced by quick movements or pressure over the areas; he rated this pain as 158 
an 8/10 on the Numeric Pain Rating Scale (NPRS).  159 
The Activity Measure for Post-Acute Care (AM-PAC), a 6-click short-form assessment, 160 
was developed by physical and occupational therapists at the Cleveland Clinic Health System 161 
based on the initial assessment created by researchers at Boston University.11 The scoring of the 162 
AM-PAC is a scale from 1 (patient required total assistance for the task) to 4 (patient required no 163 
assistance). The patient scored an 18/24 on the AM-PAC at the IE. See Appendix 3 for test 164 
descriptions and psychometric properties. 165 
The Functional Independence Measure (FIM) was utilized to measure the amount of 166 
independence and/or assistance required for specific tasks. See Appendix 4 for scoring. His 167 
initial FIM scores were as follows: bed mobility 5 (stand-by assistance), transfers 4 (contact 168 
guard assist (CGA)), gait 2 (total assistance), and stairs 0 (unable to assess/perform).  169 
Despite the lack of information regarding validity and reliability for oncologic 170 
populations specifically, the FIM and the AM-PAC were utilized with every patient at this 171 
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ACCC for a comprehensive understanding of patient mobility and assistance/independence. 172 
Ultimately, due to the patient’s functional ability and increased fatigue at the time of the IE, there 173 
was a lack of functional outcome measures performed. See Table 3 for results of test and 174 
measures. 175 
 176 
 177 
Clinical Impression: Evaluation, Diagnosis, Prognosis 178 
 179 
After reviewing the patient’s chart, he was previously independent and experienced 180 
severe decline in function and progressive weakness including bowel/bladder incontinence due 181 
to an unknown etiology. However, at his IE, he presented with greater functional ability than 182 
expected for his age, diagnosis, and initial chart review. Despite the notable weakness in his 183 
BLE, specifically the right lower extremity, his ability to activate his BLE muscles and the 184 
necessity for functional training in daily activities prompted continuation of care and 185 
appropriateness for PT intervention.  186 
The proposed POC included: therapeutic exercise to improve strength deficits; 187 
neuromuscular re-education to improve balance; self-care/home management to ensure safe and 188 
efficient navigation of his home and environment; gait training to allow for functional mobility; 189 
and therapeutic activities to target common activities this patient participated in prior to 190 
admission to the ACCC. The patient’s medical diagnosis, although truly unknown, was deemed 191 
as paraplegia with neurogenic bladder. His medical diagnosis was consistently changed due to 192 
the plethora of tests the patient underwent in the attempt to determine the root of his progressive 193 
impairments. The patient’s PT diagnoses were generalized weakness, gait abnormalities, and 194 
fatigue. See Appendix 5 for ICD-10 codes. 195 
The prognosis for this patient was initially unclear due to the unknown etiology, his 196 
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primary diagnosis of MDS, and the known complications of allo-SCTs. However, the patient’s 197 
ability at IE compared to his EC evaluation already showed promise towards recovery with 198 
medication and additional assistance from PT. Morishita et al7 determined the use of high dose 199 
corticosteroids was related to decreased strength which was more pronounced in those patients 200 
who did not receive PT services or received them at a lower frequency. Due to the research 201 
stated above, clinical judgment from the patient’s IE, and the patient’s PLOF his PT prognosis 202 
had positive influences. However, due to the uncertainty of the root causation of his progressive 203 
weakness, there were also barriers to understanding his potential from a PT standpoint.  204 
Upon IE a consult with occupational therapy (OT) and physiatry were requested. A 205 
multitude of tests were conducted to determine the root cause of his progressive weakness and 206 
included: blood screens, lumbar punctures, bronchoscopies, MRIs and CT scans. Re-evaluations 207 
at the ACCC were performed at the tenth visit which included strength and sensation testing, gait 208 
distance, and any additional measures deemed necessary.    209 
The POC included targeting his functional decline through improvement in his strength, 210 
balance, endurance, and gait efficiency. Due to the patient’s weakness and quick fatigability, 211 
interventions had to be planned appropriately to ensure the best outcomes and ability of the 212 
patient. For example, PT sessions were scheduled for the morning and ambulation was done first 213 
to ensure the patient was at his full capacity to participate. The PT goals for the patient were 214 
written at IE and were to be completed within four weeks and reassessed with each treatment 215 
session. At the ACCC, the goals were all short-term goals (STG) with the long-term goal of 216 
discharge home at the patient’s PLOF. See Appendix 6 for STG. 217 
 218 
Intervention and Plan of Care    219 
 The patient’s POC and progress were coordinated with and communicated to the OT, 220 
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nurses, and physiatry doctors. Each treatment session was documented through an electronic 221 
medical record database. The patient was educated and cued using his preferred learning style of 222 
demonstration, verbal and tactile cueing.  223 
 At IE, the patient was educated on the importance of out of bed (OOB) activities and was 224 
recommended to be OOB for 6-8 hours daily to improve cardiopulmonary function. He was 225 
instructed to complete his home exercise program (HEP) to improve his BLE strength and 226 
ambulation three times daily to improve his mobility. His wife was present for all treatment 227 
sessions and agreed with the POC. The interventions were based on impairments noted during 228 
his IE including strength deficits, balance impairments, gait abnormalities, and overall decreased 229 
functional independence.  230 
After the patient’s IE, the patient was scheduled for PT five times weekly with additional 231 
weekend PT if requested. During every session, the patient completed seated and/or standing 232 
exercises to improve BLE muscular strength, endurance, balance, and mobility. See Table 4 for 233 
descriptions of seated and standing exercises. Initially, the patient did not have the strength to 234 
complete all of the seated exercises independently and required active assisted range of motion 235 
(AAROM). When the patient completed ten repetitions of his seated and standing exercises 236 
without rest breaks, his exercises were progressed by increasing repetitions or focusing on 237 
functional activities.  238 
Lee et al8 noted that use of high dose steroid therapy, such as in this patient’s case, led to 239 
steroid myopathy which affects proximal lower muscles greater, with the quadriceps muscle 240 
affected the most. This patient showed this trend with proximal weakness and specifically he 241 
showed quadricep weakness during gait with episodes of knee buckling (KB). Therefore, the PT 242 
focused on strengthening proximal musculature while maintaining strength in distal musculature. 243 
At each session, transfers and gait training were assessed using FIM scores and distance of 244 
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ambulation. See Table 5 for FIM scores and ambulation distances. Gait training over even 245 
surfaces with non-skid socks was utilized to help improve functional mobility and BLE 246 
strengthening. Initially the patient required the use of a RW (Drive Medical, Port Washington, 247 
NY) and CGA from the PT. He initially showed increased episodes of BLE KB, approximately 248 
seven episodes, with turning, longer ambulation distances, and increased fatigue. Therefore, the 249 
patient ambulated first during a treatment session to maximize available strength. As he 250 
progressed, his KB decreased by approximately 75% and the patient recovered from KB 251 
episodes independently. By treatment five he ambulated after he completed his exercises, which 252 
showed an improvement in endurance. Based on clinical judgement, the patient required more 253 
assistance from the PT without a RW. Therefore, it was determined he would benefit from using 254 
a RW to be more independent. The distance of ambulation per day was determined via patient 255 
tolerance and frequency of KB as a sign of fatigue. His endurance was also assessed through the 256 
number of patient requested rest breaks during ambulation. The patient’s anemia was also 257 
considered as a factor leading to fatigue, as anemia has shown an association with decreased 258 
6MWT distances.7  259 
Balance was also targeted because allo-SCT patients have demonstrated decreased 260 
dynamic and static balance and strength after SCT.14 Therefore, both strength and balance were 261 
interventions to ensure his safety with functional mobility. Balance interventions included 262 
narrow base of support stance, tandem stance, and single leg stance. The patient was instructed to 263 
hold the positions for as long as possible or a maximum of 30 seconds. Initially, the patient was 264 
allowed to use his RW for support with his upper extremities. Once he was able to maintain a 265 
position for 30 seconds, the intervention progressed to no support then further progressed to 266 
maintain a position with eyes closed. See Table 6 for balance exercises.  267 
At each treatment session, the patient’s goals, FIM scores, and AM-PAC scores were 268 
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assessed and documented. Therefore, the PT understood the patient’s short-term progress and 269 
determined if the patient was compliant with his HEP.  270 
 271 
 272 
 273 
 274 
 275 
 276 
 277 
 278 
 279 
TIMELINE 280 
 281 
 282 
 283 
 284 
OUTCOMES          285 
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 At IE, the patient had decreased strength, FIM scores, AM-PAC scores, and ambulation 286 
distance. At the final visit in acute care, the patient had improved in all categories. He was 287 
transferred to the inpatient rehabilitation floor within the hospital where he showed further 288 
improvements prior to his discharge home. See Tables 2 and 3 for final examination scores. 289 
Although difficult to assess, through the measurement of breaks required, total distance 290 
ambulated, and instances of KB, the patient made marked gains at final discharge from the acute 291 
floor.  292 
 Despite making vast improvements in functioning, his diagnosis still remained 293 
paraplegia with unclear etiology. He continued to have tests done including daily blood counts, 294 
bronchoscopies, MRI scans, and x-rays as symptoms required.  295 
 The patient’s adherence and tolerability to each session were determined through ability 296 
to perform familiar and new exercises, ambulation distance, and pain and fatigue levels. His 297 
blood counts often correlated with his fatigue levels and ambulation distance. See Appendix 7 298 
for lab values. His wife stayed at the hospital every night and was adamant about him performing 299 
his exercises and staying OOB. The patient had a strong motivation to participate in PT as his 300 
goal was to return home with the same PLOF.  301 
 The only unanticipated event was the patient contracted pneumonia and clostridium 302 
difficile while in the hospital. He subsequently required contact isolation, but the infections were 303 
successfully treated prior to discharge.  304 
 305 
DISCUSSION  306 
 This case report described the PT interventions for an individual who underwent an allo-307 
SCT and consequently had a multitude of long-term complications. His complications caused 308 
progressive weakness, sensory impairments, and decreased functional mobility. PT services were 309 
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provided to address these impairments with the patient’s goal of being discharged home at the 310 
same PLOF. Specifically, this patient wanted to walk again without an assistive device.   311 
The long-term systemic complications due to GVHD after an allo-SCT were evident with 312 
this patient. Similar to the results by Morris et al,6 this patient was adherent with PT interventions 313 
except for when his condition worsened (during low hemoglobin levels and other contracted 314 
illnesses). Also, consistent with the research, he consequently had proximal weakness due to 315 
long-term corticosteroid use. His weakness was a barrier to ambulation and performing activities 316 
of daily living (ADLs) independently.  317 
Strengths of the approach to this case were the clinician’s knowledge of allo-SCTs, 318 
cGVHD, and MDS, the support of other health care clinicians, and the determination of the 319 
patient. Additionally, having inpatient rehabilitation within the hospital allowed this patient to 320 
transfer internally and receive the care he required. Limitations of this case report include lack of 321 
outcome measures utilized and unclear etiology of the patient’s diagnosis. 322 
The outcomes revealed improvements in ambulation distance with decreased KB, 323 
independence with ADLs such as transfers, and improved strength. The primary take away 324 
lessons from this case report is the benefit of PT for individuals with cancer who undergo allo-325 
SCTs and acquire GVHD. Also, it is important to understand lab values, patients’ fatigue, and 326 
pain levels to determine activity tolerance. Potential implications for clinical practice stemming 327 
from this case report include a focus for clinicians on strength and ADL function in oncology 328 
rehabilitation, as well as the importance of additional research on long-term complications from 329 
allo-SCTs and GVHD.   330 
With the increase in prevalence of allo-SCTs, it is estimated approximately 500,000 long 331 
term survivors of allo-SCTs by 2020.15 Many research articles depict the long-term 332 
complications of allo-SCTs which can cause severe impairments and even mortality.15 Due to 333 
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these complications, patients require a team of health professionals and greater surveillance to 334 
manage the long-term effects of allo-SCTs. Additionally, any individual receiving an allo-SCT is 335 
estimated to have at least a 30% lower life expectancy than the general population.16 Further 336 
research is required in areas of prevention and management of long-term complications of allo-337 
SCTs to optimize treatment. Currently, research on the effects of exercise on GVHD being 338 
performed in animal models and has proven mice with cGVHD had less deterioration of physical 339 
capacity with increased physical activity.17 Research needs to continue on allo-SCTs in humans 340 
due to the increased prevalence and common complications that result in decreased function and 341 
mortality.  342 
 343 
 344 
 345 
 346 
 347 
 348 
 349 
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 TABLES and FIGURES (Max of six total)  401 
Table 1: Stem Cell Transplant Information 
Type of Stem Cell 
Transplant 
Mechanism of Treatment Common Complications  
Autologous -Patient undergoes chemotherapy to destroy 
cancerous cells and decrease the production of 
blood cells4  
-Patient’s own stem cells are reintroduced4  
-Stem cells differentiate into new healthy blood 
cells4  
-Anemia and thrombocytopenia4  
-Deconditioning4  
-Chemotherapy induced peripheral 
neuropathy (CIPN)5  
-Cancer related fatigue4  
-Decreased immune function4 
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Allogenic -Matched donors stem cells are collected4 
-Patient undergoes chemotherapy to destroy 
cancerous cells4   
-Patient takes immunosuppressants to weaken 
immune system and attempt to prevent graft-
versus-host-disease (GVHD)4 
-Patient also takes prophylactic antimicrobial 
agents to decrease the risk of infection from the 
immunosuppressants4 
-Stem cells differentiate into new healthy cells4  
-Anemia and thrombocytopenia4 
-Deconditioning (muscle weakness and 
loss of muscle mass)5 
-Steroid myopathy (proximal muscle 
weakness) due to glucocorticoid 
treatment for GVHD5  
-CIPN5 
-Cancer related fatigue4  
-GVHD and associated side effects due 
to both the disease and treatment for 
GVHD4  
-Decreased immune function  
-Increased risk for long term 
complications such as: 
osteopenia/osteoporosis, osteonecrosis, 
fasciitis, polymyositis, polyneuropathy, 
fatigue5 
 
 402 
 403 
 404 
Table 3: Tests & Measures 
Tests & Measures Initial Evaluation Results 
Light Touch Sensation WNL 
Manual Muscle Testing Decreased strength R > L  
5 Times Sit to Stand  Unable to asses due to safety concerns, inability to 
perform correctly, and continuous education required 
during task  
FIM Bed Mobility Score 5 (SBA)  
FIM Transfer Score  4 (CGA/Minimal assistance)  
Ambulation Distance 2 feet  
FIM Ambulation Score 2 (Total Assist)  
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FIM Stairs  0 (Unable to assess/perform) 
AM-PAC Basic Mobility (6-Click)  18  
WNL = within normal limits, R = right, L = left, SBA = stand by assistance, CGA = contact guard assist, FIM 
(Functional Independence Measure) 
 405 
 406 
 407 
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APPENDICES (Supplemental tables and figures beyond max of six) 409 
 410 
 411 
 412 
 413 
Appendix 1: Medication List 
Inpatient Medications  Outpatient Medications  
Amlodipine (NORVASC) Vitamin D3 
Cefepime (MAXIPIME) Contour test strips  
Cholecalciferol (vitamin D3)  Lomotil  
Dexamesthosone (DECADRON)  Tricor  
Fenofibrate nanocrystalized (TRICOR)  Neurontin 
Folic acid (Vitamin B-9) Glucotrol 
Gabapentin (NEURONTIN)  Levaquin 
Insulin glargine (LANTUS) Magnesium oxide 
Insulin lispro (HumaLOG) Metformin (Glucophage XR)  
Linezolid (ZYVOX) Zofran-ODT  
Neomycin-bacitracin-polymyxin B (NEOSPORIN) Protonix 
Pantoprazole (PROTONIX)  Pentamidine inhalation 
Potassium chloride Miralax 
Prednisone (DELATSONE) Deltasone 
Psyllium husk (METAMUCIL) Senokot-S  
Rosuvastatin (CRESTOR) Rapamune 
Sirolimus (RAPAMUNE) Valtrex 
Sucralfate (CARAFATE)  VFEND  
Thiamine (Vitamin B-1)   
ValACYclovir (VALTREX)  
Voriconazole (VFEND)   
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Appendix 2: Systems Review Results 
Cardiovascular/Pulmonary  BP 121/74 
HR 97 
O2 97% 
BMI: 22.31 kg/m2 
Musculoskeletal Decreased gross strength in BLE, R>L 
Atrophy in bilateral thighs  
Neuromuscular AxO x 3 
Decreased DTRs patella and Achilles R> L  
Sensation to touch decreased R>L up to upper ¼ of R thigh 
Integumentary WNL 
Communication WNL 
Affect, Cognition, 
Language, Learning Style 
Mood and affect appropriate 
Cognition normal 
English language 
Responded well to multiple learning styles including auditory and visual  
BP = blood pressure, HR = heart rate, O2 = oxygen saturation, BMI = body mass index, BLE = bilateral 
lower extremities, R = right, L = left, AxO = alert and oriented, DTRs = deep tendon reflexes, WNL = 
within normal limits,  
 416 
 417 
Appendix 3: Tests & Psychometric Properties 
Test Description of Test Psychometric Properties 
Manual Muscle 
Testing (MMT) 
-Patient is asked to maintain a 
muscle contraction with resistance 
provided by the physical therapist  
-Controversial in the literature 
-Good concurrent validity compared to handheld 
dynamometers9 
Numeric Pain 
Rating Scale 
(NPRS)  
-Patient subjectively rates pain from 
0-10 with 10/10 meaning the patient 
is in severe pain 
-Excellent interrater reliability, internal 
consistency, concurrent, and convergent 
validity10  
AM-PAC Basic 
Mobility  
-Determines the amount of assistance 
necessary for the patient to complete 
turning over in bed; sitting down on 
and standing up from a chair with 
arms; moving from lying on back to 
sitting on the side of the bed; moving 
to and from a bed to a chair; walking 
in a hospital room; and climbing 3-5 
stairs with a railing  
-Excellent interrater reliability (0.849) amongst 
physical therapists11 
-Internal consistency reliability for the basic 
mobility scale was 0.9612 
-Validity determined to be strong based on 
correlation to FIM scores at discharge12 
Functional 
Independence 
Measure (FIM) 
-Measures amount of independence 
the patient has, or the assistance 
required from the physical therapist 
to complete the task  
-Reliability for older adult and geriatric 
population was excellent (test-retest reliability 
0.98) 13 
-Interrater reliability (0.95) for patients with 
different diagnoses and impairments13 
 418 
 419 
 420 
 421 
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Appendix 4: Functional Independence Measure (FIM) Scoring 
 Transfer: Bed, Chair, 
Wheelchair 
Locomotion: 
Walk/Wheelchair 
Stairs 
0 Activity did not occur due to 
safety/medical limitation or 
refusal  
Activity did not occur due to 
safety/medical limitation or 
refusal 
Activity did not 
occur due to safety, 
medical condition, 
refusal 
1: Total Assist Patient performs less than 25% of 
transfers on and off a bed to a 
wheelchair (WC) or chair or 
requires two helpers (includes 
setup) or mechanical lift, or 1 
helper transfers patient lift and 
lower while 1 helper supervises  
Patient moves less than 50 feet 
or requires 2 helpers (helper 
assists with managing IV pole, 
O2 tank, or WC) 
Less than 4 stairs or 2 
helpers, tried by 
unable or unsafe  
2: Max Assist Patient transfers self on and off a 
bed to a WC or chair and requires 
lifting and lowering assistance or 
performs 25-49% of effort 
required  
Patient moves greater than or 
equal to 150 feet and requires 
steadying or touching assist  
4-6 stairs with 1 
helpful 
3: Moderate 
Assist  
Patient transfers self on and off a 
bed to a WC or chair and requires 
lifting or lowering assistance or 
moving 2 limbs or performs 50% 
to 74% of the effort required  
Patient moves greater than or 
equal to 150 feet and requires 
lifting assistance  
Full flight with lifting 
assist 
4: Minimum 
Assist/Contact 
Guard Assist  
Patient transfers self on and off a 
bed to a WC or chair and requires 
touching or steadying assistance 
or lifting one limb or 75% or 
greater of the effort required 
Patient moves greater than or 
equal to 150 feet and requires 
steadying or touching assist 
Full flight with 
steady or touching 
assist  
5(Supervision, 
Stand-By 
Assist)  
Patient transfers self on and off a 
bed to a WC or chair and requires 
supervision, or setup (includes 
positioning chair, locking 
wheelchair, 
applying/removing/adjusting leg 
rests) or verbal cues  
Patient moves greater than or 
equal to 150 feet and requires 
cueing supervision, standby 
assist  
Full flight with 
supervision, cueing, 
stand-by assist  
5 (Household 
Exception) 
 Patient walks short distance 
(50+ feet) with or without 
device, or takes more time and 
requires no helper 
4-6 stairs with or 
without device and 
no helper  
6 (Modified 
Independent)  
Patient transfers self and off a bed 
to a WC or chair and uses and 
assistive device handrail, armrest, 
slide board, walker etc.) or slower 
pace (3x slower) or safety 
concerns 
Patient moves greater than or 
equal to 150 feet, uses device, 
takes 3x longer, if WC is being 
scored, patient also turns, 
maneuvers to table, bed and 
toilet, maneuvers over a door 
sill, and negotiates a 3% grade  
Full flight with 
device or handrail 
and no helper 
7 Patient transfers self on and off a 
bed to a WC or chair at a usual 
Patient moves greater than or 
rqual to 150 feet without 
Full flight without 
device or handrail at 
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(Independent)  pace (no devices without use of 
handrails, armrests, or devices, 
includes managements of WC 
parts) 
device (walkers or WC) safe, 
timely, this score is not to be 
used when patient uses WC for 
locomotion  
usual time with no 
helper  
 426 
 427 
Appendix 5: ICD-10 Codes 
ICD-10 Code Code Meaning 
R53 Malaise and fatigue 
R26 Abnormalities of gait and mobility 
R26.2 Difficulty in walking, not elsewhere classified 
R29.3 Abnormal posture 
M62.81 Muscle weakness (generalized)  
M62.5 Muscle wasting and atrophy, not elsewhere classified 
R26.81 Unsteadiness on feet 
G89.3 Neoplasm related pain (acute) (chronic)  
 428 
Appendix 6: Short-Term Goals (4 weeks) 
1 Patient will be compliant with out of bed (OOB) recommendations for 6-8 hours per day in 
order to improve cardiopulmonary functioning. 
2 Patient will be independent with HEP to improve strength/conditioning. 
3 Patient will be independent with all bed mobility to improve functional independence. 
4 Patient will be independent with all transfers in order to improve functional independence.  
5 Patient will ambulate over an even surface at modified independent for 150 feet in order 
increase functional mobility. 
 429 
Appendix 7: Complete Blood Count Trends 
Visit Number White Blood Cells  Hemoglobin Platelets  
1 2.4 9.3 452 
2  4.4 9.5 507 
3 4.4 9.1 396 
4  4.6 10.8 426 
5  4.3 9.2 268 
6  5.4 8.9 269 
7  6.4 8.6 255 
8  10.3 10.1 241 
9  10.9 9.8 241 
10  16.2 11.4 281 
11  13.2 9.6 249 
12  14.3 8.2 220 
13  13.3 10.1 217 
Normal values for white blood cells: 4.0-11.0K/uL 
Normal values for hemoglobin: Male: 14.0-18.0 g/dL, Female: 12.0-16.0 g/dL 
Normal values for platelets: 140 – 440 k/uL 
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CARE Checklist 437 
CARE Content Area Page 
1. Title – The area of focus and “case report” should appear in the title 1 
2. Key Words – Two to five key words that identify topics in this case report 1 
3. Abstract – (structure or unstructured) 
a. Introduction – What is unique and why is it important? 
b. The patient’s main concerns and important clinical findings. 
c. The main diagnoses, interventions, and outcomes. 
d. Conclusion—What are one or more “take-away” lessons? 
2 
4. Introduction – Briefly summarize why this case is unique with medical literature 
references. 
3-5 
5. Patient Information 
a. De-identified demographic and other patient information. 
b. Main concerns and symptoms of the patient. 
c. Medical, family, and psychosocial history including genetic information. 
d. Relevant past interventions and their outcomes. 
5-6 
6. Clinical Findings – Relevant physical examination (PE) and other clinical findings 7 
7. Timeline – Relevant data from this episode of care organized as a timeline (figure 
or table). 
12 
8. Diagnostic Assessment 
a. Diagnostic methods (PE, laboratory testing, imaging, surveys). 
b. Diagnostic challenges. 
c. Diagnostic reasoning including differential diagnosis. 
d. Prognostic characteristics when applicable. 
8-9 
9. Therapeutic Intervention 
a. Types of intervention (pharmacologic, surgical, preventive). 
b. Administration of intervention (dosage, strength, duration). 
c. Changes in the interventions with explanations. 
9-11 
10. Follow-up and Outcomes 
a. Clinician and patient-assessed outcomes when appropriate. 
b. Important follow-up diagnostic and other test results. 
c. Intervention adherence and tolerability (how was this assessed)? 
d. Adverse and unanticipated events. 
12-13 
11. Discussion 
a. Strengths and limitations in your approach to this case. 
b. Discussion of the relevant medical literature. 
c. The rationale for your conclusions. 
13-14 
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     438 
d. The primary “take-away” lessons from this case report. 
12. Patient Perspective – The patient can share their perspective on their case. N/A 
13. Informed Consent – The patient should give informed consent. 1,5 
